KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Capital Expenditures (2018 - 2024)

Esperion Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $167000.0 for Q3 2024.

  • For Q3 2024, Capital Expenditures changed N/A year-over-year to $167000.0; the TTM value through Jun 2025 reached $167000.0, up 11.33%, while the annual FY2024 figure was $317000.0, N/A changed from the prior year.
  • Capital Expenditures reached $167000.0 in Q3 2024 per ESPR's latest filing, up from $77000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $721000.0 in Q4 2020 to a low of -$628000.0 in Q3 2020.